HK Stock Market Move | ZHAOKE OPHT-B(06622) rises by more than 5% again, new drug for presbyopia approved by FDA for market launch.

ZHAOKE OPHTH-B (06622) rose by more than 5%, as of press time, up by 5.28% to HK$3.79, with a total transaction volume of 6.119 million Hong Kong dollars. On the news front, on the evening of January 29th, Zhaoke Ophthalmology announced that its partner, Tenpoint Therapeutics, Ltd., had received regulatory approval from the US FDA for the commercialization of Brimonidine and Brinzolamide eye drops (2.75% / 0.1%). These eye drops were known as BRIMOCHOL PF during clinical trials, and will be marketed in the US under the name YUVEZZI as an innovative drug for treating presbyopia. The announcement indicated that for Zhaoke Ophthalmology, this approval is a strong catalyst before implementing its commercialization strategy. The company has established a network of partners for BRIMOCHOL PF, which currently includes eight commercial partners in the Asia-Pacific region (including South Korea, Australia, New Zealand, Thailand, Indonesia, Taiwan/Hong Kong/Macau, Singapore, and Vietnam) and the Middle East. With FDA approval, Zhaoke expects to accelerate the launch of this drug, marking an important global milestone.